Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Drug Profile

Influenza A virus vaccines (pandemic) - Protein Sciences Corporation

Alternative Names: ASP 7373; Avian influenza (bird flu) vaccine - Protein Sciences Corporation/UMN Pharma; H7-rHA; HA vaccine for H5N1 (UMN 0501) - Protein Sciences Corporation; HA vaccine for H9N2 (UMN 0901) - Protein Sciences Corporation; Influenza A (H1N1) vaccine - Protein Sciences Corporation/Vaxine; Influenza A virus H5N1 vaccine - UMN Pharma; Influenza A virus H7N9 vaccine - Protein Sciences Corporation; Panblok; PanBlok; Panblok H1/2009; Panblok-H7; Pandemic H5N1 influenza vaccine - Protein Sciences Corporation/UMN Pharma; Pandemic influenza virus (swine flu) vaccine - Vaxine; Recombinant H5 (rH5) pandemic influenza vaccine (Panblok) - Protein Sciences Corporation; Recombinant haemagglutinin (rHA) influenza vaccine; Recombinant influenza H5N1 vaccine (UMN-0501) - UMN Pharma; UMN 0901; UMN-0501

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Protein Sciences Corporation
  • Developer Astellas Pharma; Ildong Pharmaceutical; Protein Sciences Corporation; UMN Pharma; Vaxine
  • Class Influenza A vaccines; Influenza A virus H1N1 vaccines; Influenza A virus H5N1 vaccines; Influenza A virus H7N9 vaccines; Influenza A virus H9N2 vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Influenza A virus H5N1 subtype
  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H5N1 subtype; Influenza A virus H7N9 subtype
  • Phase I Influenza A virus H1N1 subtype
  • Preclinical Influenza A virus H9N2 subtype

Most Recent Events

  • 20 Sep 2017 Biomedical Advanced Research and Development Authority plans a phase II trial in Healthy volunteers (Adjuvant treatment, Prevention) in USA (NCT03283319)
  • 01 Sep 2017 Phase-II clinical trials in Influenza-A virus H7N9 subtype (Prevention, Adjunctive treatment) in USA (IM) (NCT03283319)
  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top